Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Find generic entry opportunities
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Cyclosporin galenic forms|
|Abstract:||Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.|
|Inventor(s):||Cavanak; Thomas (Biel-Benken, CH), Posanski; Ulrich (Freiburg, DE)|
|Assignee:||Novartis AG (Basel, CH)|
Patent Claim Types:|
see list of patent claims
|Composition; Dosage form;|
Back Citations: 34th percentile
Forward Citations: 0th percentile
|Patent Number||Expiration Date|
|7,511,014||March 31, 2013|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||8903804.6||Feb 20, 1989|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.